Tien Phyllis C, Cole Stephen R, Williams Carolyn Masters, Li Rui, Justman Jessica E, Cohen Mardge H, Young Mary, Rubin Nancy, Augenbraun Michael, Grunfeld Carl
Department of Medicine, University of California at San Francisco, San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA.
J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):461-6. doi: 10.1097/00126334-200312150-00003.
To estimate the incidence of lipoatrophy and lipohypertrophy among HIV-infected and HIV-uninfected women from the Women's Interagency HIV Study.
Eight hundred fifteen women with semiannual data on self-report of bidirectional change in body fat, anthropometric measurements, weight, and bioelectric impedance analysis were included in a 30-month incidence analysis.
Lipoatrophy and lipohypertrophy in both peripheral (arms, legs, and buttocks) and central (waist, chest, and upper back) sites were defined by self-report of either a decrease or an increase in a body fat region over the previous 6 months that was confirmed by a corresponding change in anthropometric measurement.
Weight and total body fat increased in HIV-uninfected women but remained stable in HIV-infected women over 30 months. Among HIV-infected women, the incidence of peripheral (relative hazard, 2.1; 95% confidence interval [CI], 1.4-3.3) and central (relative hazard, 1.9; 95% CI, 1.2-2.8) lipoatrophy was about double that among HIV-uninfected women, after adjustment for age and race. The incidence of peripheral lipohypertrophy appeared lower among HIV-infected women than among HIV-uninfected women (relative hazard, 0.8; 95% CI, 0.6-1.1), while the incidence of central lipohypertrophy did not differ by HIV status. Of HIV-infected women with 2 of 4 lipodystrophy outcomes, most (81%) had combined peripheral and central lipoatrophy or combined peripheral and central lipohypertrophy. Only 14% of these women had both peripheral lipoatrophy and central lipohypertrophy.
These prospective data suggest that lipoatrophy, affecting both peripheral and central sites, predominates in HIV-infected women. The simultaneous occurrence of peripheral lipoatrophy and central lipohypertrophy was uncommon.
通过女性机构间HIV研究,评估HIV感染女性和未感染HIV女性中脂肪萎缩和脂肪肥大的发生率。
对815名女性进行为期30个月的发病率分析,这些女性每半年有一次关于身体脂肪双向变化、人体测量、体重和生物电阻抗分析的自我报告数据。
外周(手臂、腿部和臀部)和中央(腰部、胸部和上背部)部位的脂肪萎缩和脂肪肥大通过自我报告来定义,即过去6个月内身体脂肪区域的减少或增加,并经人体测量的相应变化证实。
在30个月内,未感染HIV的女性体重和全身脂肪增加,而感染HIV的女性则保持稳定。在感染HIV的女性中,调整年龄和种族后,外周(相对风险,2.1;95%置信区间[CI],1.4 - 3.3)和中央(相对风险,1.9;95% CI,1.2 - 2.8)脂肪萎缩的发生率约为未感染HIV女性的两倍。感染HIV的女性中外周脂肪肥大的发生率似乎低于未感染HIV的女性(相对风险,0.8;95% CI,0.6 - 1.1),而中央脂肪肥大的发生率在HIV感染状态不同的女性中无差异。在有4种脂肪代谢障碍结果中的2种的感染HIV的女性中,大多数(81%)患有外周和中央脂肪萎缩合并或外周和中央脂肪肥大合并。这些女性中只有14%同时患有外周脂肪萎缩和中央脂肪肥大。
这些前瞻性数据表明,脂肪萎缩在外周和中央部位均有发生,在感染HIV的女性中占主导。外周脂肪萎缩和中央脂肪肥大同时出现的情况并不常见。